Newsroom

Sorted by: Latest
-

In Response to a Broader FDA Investigation, ByHeart Initiates a Voluntary Recall of Two Batches of Infant Formula

NEW YORK--(BUSINESS WIRE)--ByHeart, a next-generation baby nutrition company, announced today that, out of an abundance of caution, it has chosen to voluntarily recall two batches of ByHeart Whole Nutrition Infant Formula following notification from the U.S. Food and Drug Administration (FDA) of a broader ongoing investigation into a recent outbreak of infant botulism. Infant botulism is a rare but potentially fatal illness that presents a serious threat to the health of infants which occurs wh...
-

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the on...
-

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from cardiovascular magnetic re...
-

United States Otorhinolaryngology KOLs Fair-Market Value Compensation Rates Report 2025: An Independent Reference for Negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "United States Fair-Market Value Compensation Rates for Otorhinolaryngology KOLs" report has been added to ResearchAndMarkets.com's offering. This report presents fair-market value (FMV) hourly and half-day compensation rates for U.S. KOLs - Otorhinolaryngology, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national and local). Thought Leader Compensation US Otorhinolaryngology These defensible market-based rat...
-

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

RAHWAY, N.J.--(BUSINESS WIRE)--Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial...
-

Real Reaches Settlement in Principle in Litigation With Former CFO

MIAMI--(BUSINESS WIRE)--The Real Brokerage Inc. (NASDAQ: REAX), a leading real estate technology platform redefining the industry through innovation and culture, today announced that, on Nov. 5, 2025, it reached a settlement in principle in the litigation with its former Chief Financial Officer, Michelle Ressler. The court action has been dismissed by the court. Pursuant to the settlement in principle, Real will make no payment to Ms. Ressler. In addition, pursuant to the settlement in principl...
-

FIS Launches Innovative Asset Servicing Management Suite to Unlock Operational Efficiency Across Asset Servicing

JACKSONVILLE, Fla.--(BUSINESS WIRE)--FIS launches new Asset Servicing Management Suite, a suite of automated and integrated solutions which help unlock operational efficiency....
-

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six months. The reductions were sustained through 12 months. Olezarsen showed a highly statist...
-

Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership

WASHINGTON--(BUSINESS WIRE)--Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary'...
-

American Gridwork Partners Acquires PMT Site to Accelerate Modernization of American’s National Grid Infrastructure Network

NASHVILLE, Tenn.--(BUSINESS WIRE)--American Gridwork Partners (AGP), a Legacy Holdings vehicle dedicated to modernizing America’s sub-regional and last-mile energy, water, and data infrastructure grids, today announced its acquisition of PMT Site, a leading Nashville-based provider of underground utility and site infrastructure services. This strategic transaction marks the launch of AGP’s year-long effort to identify the nation’s most capable infrastructure service providers and form a scalabl...